Lirum Therapeutics (Lirum Therapeutics) EBITDA Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lirum Therapeutics's EBITDA for the three months ended in Dec. 2023 was $-0.30 Mil. Lirum Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Lirum Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

Lirum Therapeutics EBITDA Margin % Historical Data

The historical data trend for Lirum Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics EBITDA Margin % Chart

Lirum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

EBITDA Margin %

Lirum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
EBITDA Margin %	-	-	-	-	-

Competitive Comparison of Lirum Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Lirum Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lirum Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lirum Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lirum Therapeutics's EBITDA Margin % falls into.

Lirum Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lirum Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-2.194	/	0
	=	%

Lirum Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.298	/	0
	=	%

Lirum Therapeutics (NAS:LRTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Lirum Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.lirumtx.com

Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines